Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | 7-year outcomes of tremelimumab, durvalumab and sorafenib in first-line HCC

Ghassan Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the seven-year overall survival results of the Phase III HIMALAYA study (NCT03298451), which compared tremelimumab plus durvalumab with sorafenib in first-line unresectable hepatocellular carcinoma (HCC). The study demonstrated a significant overall survival benefit with the tremelimumab/durvalumab combination. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Welcome, everybody, to Madrid. We are delighted on behalf of our colleagues to update you on the Himalaya study. Wow, can you believe it’s seven years? We’re going to present the seven-year overall survival and overall survival by the tumor response measures for the Himalaya study, if you recall, one dose only of Tremelimumab as NTC LA4 plus monthly treatment with Nivolumab under Atezolizumab or actually Durvalumab...

Welcome, everybody, to Madrid. We are delighted on behalf of our colleagues to update you on the Himalaya study. Wow, can you believe it’s seven years? We’re going to present the seven-year overall survival and overall survival by the tumor response measures for the Himalaya study, if you recall, one dose only of Tremelimumab as NTC LA4 plus monthly treatment with Nivolumab under Atezolizumab or actually Durvalumab. We have found, after looking into the whole participants, 1,200 or close to 1,200 of them, that the overall survival that was reported initially at 16.43 months and compared to the 13.77 for the Sorafenib. At now seven years, or in other words, 84 months, we have 14% survival for the stride regimen, Tremelimumab versus Durvalumab, and a mere 17% for the Sorafenib. So again, the overall survival favors the stride over the Sorafenib after seven years. And to add to this, in regard to the outcome of the patients, number one survival for the ALBI scoring grade one was 23.43 months with the stride, and it was 18.92 months for the Sorafenib, and at 7 years, it was 16% for the ALBI grade 1, and it was 11% for the ALBI grade 2 and 3. So again, one more time, this is the only study that has shown so far 7 years survival outcome in regard to treatment with double checkpoint inhibitors in HCC. And it really proves one more time that this therapy is very active. And wow, this one dose only of Tremelimumab that was given seven years beforehand still is active and doing its effect after seven years. Thanks again for listening.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.